Abstract
The history of neuroleptics started with the discovery of chlorpromazine. Chlorpromazine, a phenothiazine derivative related to promethazine (an antihistamine) and to diethazine (an antiparkinson agent), was initially used in anesthesia to potentiate the narcotic effect of pethidine.1 Chlorpromazine produced a state of indifference without loss of consciousness, and the authors suggested its potential usefulness in psychiatry and obstetrics. Delay et al.2 first studied the therapeutic effects of chlorpromazine in psychotic patients and discovered its specific antipsychotic action. Chlorpromazine became the archetype of a new class of drugs, which were called neuroleptics. The most prominent pharmacological activities of chlorpromazine were reported 1 year later.3 For several years, neuroleptic activity was considered to be an exclusive property of a few phenothiazine derivatives closely related to chlorpromazine and of the Rauwolfia alkaloid reserpine.4
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Laborit, H., Huguenard, P., and Alluaume, R., 1952, Presse Med. 60: 206–208.
Delay, J., Deniker, P., Harl, J. M., and Grasset, A., 1952, Ann. Med. Psychol. 110: 398–403.
Courvoisier, S., Fournel, J., Ducrot, R., Kolsky, M., and Koetschet, P., 1953, Arch. Int. Pharmacodyn. Ther. 92: 305–361.
Weber, E., 1954, Schweiz. Med. Wochenschr. 84: 968–970.
Janssen, P. A. J., and Niemegeers, C. J. E., 1959, Arzneim. Forsch. 9: 765–767.
Janssen, P. A. J., Van de Westeringh, C., Jageneau, A. H. M., Demoen, P. A. J., Hermans, B. K. F., Van Daele, G. H. P., Schellekens, K. H. L., Van der Eycken, C. A. M., and Niemegeers, C. J. E., 1959, J. Med. Pharm. Chem. 1: 281–297.
Janssen, P. A. J., Niemegeers, C. J. E., and Schellekens, K. H. L., 1960, Arzneim. Forsch. 10: 955.
Divry, P., Bobon, J., Collard, J., Pinchard, A., and Nols, E., 1959, Acta Neurol. Psychol. Belg. 59: 337–367.
Janssen, P. A. J., 1961, Arzneim. Forsch. 11:819–824, 932–938.
Janssen, P. A. J., Niemegeers, C. J. E., and Jageneau, A. H. M., 1960, Arzneim. Forsch. 10: 1003–1005.
Ernst, A. M., and Smelik, P. G., 1966, Experientia 22: 837–838.
Ernst, A. M., 1967, Psychopharmacologia 10: 316–323.
Van Rossum, J. M., 1966, Arch. Int. Pharmacodyn. Ther. 160: 492–494.
Blaschko, H., 1957, Experientia 13: 9–12.
Montagu, K. A., 1957, Nature 180: 244–245.
Weil-Malherbe, H., and Bone, A. D., 1957, Nature 180: 1050–1051.
Carlsson, A., Lindqvist, M., and Magnusson, T., 1957, Nature 180: 1200.
Carlsson, A., and Lindqvist, M., 1963, Acta Pharmacol. Toxicol. 20: 140–144.
Andén, N. E., Roos, B. E., and Werdinius, B., 1964, Life Sci. 3: 149–158.
Burt, D. R., Enna, S. J., Creese, I., and Snyder, S. H., 1975, Proc. Natl. Acad. Sci. U.S.A. 72: 4655–4659.
Seeman, P., Chau-Wong, M., Tedesco, J., and Wong, K., 1975, Proc. Natl. Acad. Sci. U.S.A. 72: 4376–4380.
Janssen, P. A. J., Niemegeers, C. J. E., and Schellekens, K. H. L., 1965, Arzneim. Forsch. 15: 104–117.
Janssen, P. A. J., Niemegeers, C. J. E., and Schellekens, K. H. L., 1965, Arzneim. Forsch. 15: 1196–1206.
Janssen, P. A. J., Niemegeers, C. J. E., and Schellekens, K. H. L., 1966, Arzneim. Forsch. 16: 339–346.
Janssen. P. A. J., Niemegeers, C. J. E., Schellekens, K. H. L., and Lenaerts, F. M., 1967, Arzneim. Forsch. 17: 841–845.
Niemegeers, C. J. E., and Leysen, J. E., 1982, Pharm. Weekbl. 4: 71–78.
Niemegeers, C. J. E., and Janssen, P. A. J., 1979, Life Sci. 24: 2201–2216.
Janssen, P. A. J., and Niemegeers, C. J. E., 1961, Arzneim. Forsch. 11: 1037–1043.
Niemegeers, C. J. E., and Janssen, P. A. J., 1960, J. Pharm. Pharmacol. 12: 744–753.
Costall, B., and Naylor, R. J., 1980, Rev. Pure Appl. Pharmacol. Sci. 1: 3–83.
Tedeschi, D. M., Tedeschi, R. E., and Fellows, E. J., 1961, Arch. Int. Pharmacodyn. Ther. 132: 172–179.
Niemegeers, C. J. E., Lenaerts, F. M., Artois, K. S. K., and Janssen, P. A. J., 1977, Arch. Int. Pharmacodyn. Ther. 227: 238–253.
Niemegeers, C. J. E., Colpaert, F. C., Leysen, J. E., Awouters, F., and Janssen, P. A. J., 1983, Drug Dev. Res. 3 :123–135.
Niemegeers, C. J. E., Awouters, F., Van Nueten, J. M., De Nollin, S., and Janssen, P. A. J., 1978, Arch. Int. Pharmacodyn. Ther. 234: 164–176.
Niemegeers, C. J. E., Awouters, F., Lenaerts, F. M., Vermeire, J., and Janssen, P. A. J., 1982, Arch. Int. Pharmacodyn. Ther. 259: 153–165.
Falck, B., Hillarp, N.A., Thieme, G., and Torp, A., 1962, J. Histochem. Cytochem. 10:348354.
Dahlström, A., and Fuxe, K., 1964, Acta Physiol. Scand. 62 [Suppl.] 232: 1–55.
McGeer, P. L., Eccles, J. C., and McGeer, E. G., (eds.), 1978, Molecular Neurobiology of the Mammalian Brain, Plenum Press, New York, London, p. 233.
Andén, N. E., Butcher, S. G., Corrodi, H., Fuxe, K., and Ungerstedt, U., 1970, Eur. J. Pharmacol. 11: 303–314.
Gey, K. F., and Pletscher, A., 1968, Experientia 24: 335–336.
Carlsson, A., 1975, Pre-and Postsynaptic Receptors (E. Usdin and W. E. Bunney, Jr., eds.), Marcel Dekker, New York, pp. 49–55.
Westerink, B. H. C., 1979, Eur. J. Pharmacol. 56: 313–322.
Westerink, B. H. C., 1979, J. Pharm. Pharmacol. 31: 94–99.
Stawarz, R. J., Hill, H., Robinson, S. E., Setter, P., Dingell, J. V., and Sulser, F., 1975, Psychopharmacologia (Berl.) 43: 125–130.
Westerink, B. H. C., and Korf, J., 1975, Eur. J. Pharmacol. 33: 31–40.
Bartholini, G., 1976, J. Pharm. Pharmacol. 28: 429–433.
Waldmeier, P. C., and Maitre, L., 1976, J. Neurochem. 27: 589–597.
Laduron, P., de Bie, K., and Leysen, J., 1977, Naunyn Schmiedebergs Arch. Pharmacol. 296: 183–185.
Collu, R., Stefanini, E., Vernaleone, F., Marchisio, A. M., Devoto, P., and Argiolas, A., 1980, Life Sci. 26: 1665–1673.
Argiolas, A., Fadda, F., Melis, M. R., and Gessa, G. L., 1980, Pharmacol. Res. Commun. 12: 683–688.
Westerink, B. H. C., and Korf, J., 1976, Eur. J. Pharmacol. 40: 175–178.
Gudelsky, G. A., and Moore, K. E. 1977, J. Pharmacol. Exp. Ther. 202: 149–156.
Wode-Helgodt, B., and Sedvall, G., 1978, Commun. Psychopharmacol. 2: 177–183.
Zarifian, E.. Scatton, B., Bianchetti, G., Cuche, H., Loo, H., and Morselli, P. L., 1982, Arch. Gen. Psychiatry 39: 212–215.
Kendler, K. S., Heninger, G. R., and Roth, R. H., 1981, Eur. J. Pharmacol. 71: 321–326.
Asper, H., Baggiolini, M., Burki, H. R., Lauener, H., Ruch, W., and Stille, G., 1973. Eur. J. Pharmacol. 22: 287–294.
Clow, A., Theodorou, A., Jenner, P., and Marsden, C. D., 1980, Eur. J. Pharmacol. 63:135144.
Scatton, B., Glowinski, J., and Julou, L.. 1976, Brain Res. 109: 184–189.
Scatton, B.. 1981, Ear. J. Pharmacol. 71: 499–503.
Rastogi, R. B., Singhal, R. L., and Lapierre, Y. D., 1982, Gen. Pharmacol. 13: 35–40.
Post, R. M., and Goodwin, F. K., 1975, Science 190: 488–489.
Gerlach, J., Thorsen, K., and Fog, R., 1975, Psychopharmacologia (Berl.) 40: 341–350.
Hornykiewicz, O., 1973, Br. Med. Bull. 29: 172–178.
Connor, J. D., 1968, Science 160: 899–900.
McGeer, P. L., McGeer, E. G., Fibiger, H. C., and Wickson, V., 1971, Brain Res. 35: 308–314.
Butcher, S. G., and Butcher, L. L., 1974, Brain Res. 71: 167–171.
Stadler, H., Lloyd. K. G., Gadeo-Ciria, M., and Bartholini, G., 1973. Brain Res. 55: 476–480.
Stadler, H., Lloyd, K. G., and Bartholini, G.. 1974, Naunyn Schmiedebergs Arch. Pharmacol. 283: 129–134.
Guyenet, P. G., Agid, Y., Javoy, F., Beaujouan, J. C., Rossier, J., and Glowinski, J., 1975, Brain Res. 84: 227–244.
Costa, E., Cheney, D. L., Mao, C. C., and Moroni, F., 1978, Fed. Proc. 37: 2408–2414.
Buccafusco, J. J., 1982, Biochem. Pharmacol. 31:1599–1605.
Stoof, J. C., Thieme, R. E., Vrijmoed-de Vries, M. C., and Mulder, A. H., 1979, Naunyn Schmiedebergs Arch. Pharmacol. 309: 119–124.
Stoof, J. C., De Boer, T., Sminia, P., and Mulder, A. H., 1982, Eur. J. Pharmacol. 84: 211–214.
Scatton, B., 1982, Life Sci. 31: 2883–2890.
Marco, E., Mao, C. C., Cheney, D. L., Revuelta, A., and Costa, E., 1976, Nature 264: 363–365.
Hong, J. S., Yang, H.-Y, T., and Costa, E., 1978, Neuropharmacology 17: 83–85.
Bartholini, G., Stadler, H., and Lloyd, K. G., 1975, Cholinergie Mechanisms (G. P. Waser, ed.), Raven Press, New York, p. 411–418.
Reisine, T. D., Nagy, J. I., Fibiger, H. L., and Yamamura, H. I., 1979, Brain Res. 169:209214.
Zivkovic, B., Guidotti, A., and Costa, E., 1974, Mol. Pharmacol. 10: 727–735.
Gruen, P. H., Sachar, E. J., Langer, G., Altman, N., Leifer, M., Frantz, A., and Halpern, F. S., 1978, Arch. Gen. Psychiatry 35: 108–116.
Rubin, R. T., and Hays, S. E., 1980, Psychoneuroendocrinology 5:121–137.
Denef, C., and Follebouckt, J. J., 1978, Life Sci. 23: 431–436.
Denef, C., Van Nueten, J. M., Leysen, J. E., and Janssen, P. A. J., 1979, Life Sci. 25:217226.
Cronin. M. J., Cheung, C. Y., Wilson, C. B., Jaffe, R. B., and Weiner, R. I.. 1980, J. Clin. Endocrinol. Metab. 50: 387–391.
Goldsmith, P. C., Cronin, M. J., and Weiner. R. I.. 1979, J. Histochem. Cytochem. 27: 1205 1207.
Dyer, R. G., Murugaiah. K., Theodorou, A., Clow, A., Jenner, P., and Marsden, C. D., 1981, Life Sci. 28: 167–174.
Naber, D., Fischer, H., and Ackenheil, M., 1979, Commun. Psychopharmacol. 3: 59–65.
Munemura, M., Cote, T. E., Tsuruta, K.. Eskay, R. L., and Kebabian. J. W., 1980, Endocrinology 107: 1676–1683.
Leysen, J. E., 1983, Advances in Human Psychopharmacology (G. D. Burrows and J. Werry, eds.), JAI Press, Greenwich, Connecticut 3: 315–356.
Kebabian, J. W., Petzold, G. L., and Greengard, P., 1972, Proc. Natl. Acad. Sci. U.S.A. 69: 2145–2149.
Hyttel, J., 1981, Life Sci. 28: 563–569.
Watling, K. J., Dowling, J. E., and Iversen, L. L., 1979, Nature 281: 578–580.
Brown, E. M., Attie, M. F., Reen, S., Gardner, D. G., Kebabian, J., and Aurbach, G. D., 1980, Mol. Pharmacol. 18: 335–340.
Cross, A. J., and Owen, F., 1980, Eur. J. Pharmacol. 65: 341–347.
Hyttel, J., 1980, Psychopharmacology 67: 107–109.
Leysen, J. E., Gommeren, W., and Laduron, P. M., 1978, Biochem. Pharmacol. 27: 307–316.
Leysen. J. E., and Gommeren, W., 1981, J. Neurochem. 36: 201–219.
Leysen, J. E., Awouters, F., Kennis, L., Laduron, P. M., Vandenberk, J., and Janssen, P. A. J., 1981, Life Sci. 28: 1015–1022.
Burt, D. R., Creese, I., and Snyder, S. H., 1976, Mol. Pharmacol. 12: 800–812.
Riddall, D. R., and Leavens. W. J., 1978, Eur. J. Pharmacol. 51 :187–188.
Titeler, M., List, S., and Seeman, P., 1979. Commun. Psychopharmacol. 3: 411–420.
Snyder, S. H., Creese, I.. and Burt. D. R., 1975, Commun. Psychopharmacol. 1: 663–673.
Schwartz, R., Creese, I., Coyle, J. T., and Snyder, S. H., 1978, Nature 271: 766–768.
Leysen, J. E., Gommeren, W., and Van Gompel, P., 1981, Neurochem. Int. 3: 219–228.
Laduron, P., 1981, Apomorphine and Other Dopaminornimetics, Volume 1, Basic Pharmacology (G. L. Gessa and G. U. Corsini, eds.), Raven Press, New York, pp. 95–103.
Zivkovic, B., Scatton, B., Dedek, J., Worms, P., Lloyd, K. G., and Bartholini, G., 1980, Abstracts of the 12th CINP Congress Göteborg, Pergamon Press, Oxford, New York, pp. 369–370.
Haase, H.-J., 1978. Acta Psychiatr. Belg. 78: 19–36.
Davis. J. M., 1976, Arch. Gen. Psychiatry 33: 858–861.
Laduron, P. M., Janssen, P. F. M., and Leysen, J. E., 1978, Biochem. Pharmacol. 27: 317–321.
Blanchard, J. C., Boireau, A., Garret, C.. and Julou, L., 1980, Biochem. Pharmacol. 29: 2933–2938.
Köhler, C., Haglund, L. Ogren, S.-O.. and Angeby, T., 1981, J. Neural Transm. 52: 163–173.
Leysen, J. E., Niemegeers, C. J. E., Tollenaere, J. P.. and Laduron, P. M., 1978, Nature 272: 168–171.
Laduron, P. M., 1980, Psychopharmacology and Biochemistry of Neurotransmitter Receptors (H. I. Yamamura, R. W. Olsen, and E. Usdin, eds.), Elsevier/North-Holland. Amsterdam, New York, pp. 115–132.
Le Fur, G., Guilloux, F.. and Uzan, A.. 1980, Biochem. Pharmacol. 29: 267–270.
Laduron. P. M., Janssen. P. F. M., and Leysen, J. E., 1982. Eur. J. Pharmacol. 81: 43–48.
Laduron. P. M., and Leysen, J. E., 1979, Biochem. Pharmacol. 28: 2161–2165.
Cattabeni, F., Racagni, S., Spano, P. F., and Costa, E. J., 1980. Long-Term Effects of Neuroleptics. Advances in Biochemical Psychopharmacology, Volume 24, Raven Press, New York.
List, S., and Seeman. P., 1980, Advances in Biochemical Psychopharmacology, Volume 24, Long-Term Effects of Neuroleptics (F. Cattabeni, S. Racagni, P. F. Spano, and E. J. Costa, eds.), Raven Press, New York, pp. 95–102.
Clow. A., Jenner, P., and Marsden, C. D., 1979, Eur. J. Pharmacol. 57: 365–375.
Theodorou, A., Gommeren. W., Clow, A., Leysen, J., Jenner, P., and Marsden, C. D., 1981, Life Sci. 28: 1621–1627.
Murugaiah, K., Theodorou, A., Mann, S.. Clow, A., Jenner, P., and Marsden, C. D.. 1982, Nature 296: 570–572.
Owen, F., Cross, A. J., Waddington, J. L., Poulter, M., Gamble, S. J., and Crow, T. J., 1980. Life Sci. 26: 55–59.
Dawbarn, D., and Pycock. C., 1981, Ear. J. Pharmacol. 71: 233–245.
Ansoms, C., De Backer-Dierick. G., and Vereecken, J. L. T. M., 1977, Acta Psychiatr. Scand. 55: 116–122.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Springer Science+Business Media New York
About this chapter
Cite this chapter
Leysen, J.E., Niemegeers, C.J.E. (1985). Neuroleptics. In: Lajtha, A. (eds) Alterations of Metabolites in the Nervous System. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-6740-7_13
Download citation
DOI: https://doi.org/10.1007/978-1-4757-6740-7_13
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-6742-1
Online ISBN: 978-1-4757-6740-7
eBook Packages: Springer Book Archive